Janux Therapeutics (JANX) Stock Forecast & Price Target

Janux Therapeutics is viewed favorably because JANX007 is emerging as a credible PSMA TCE with early efficacy signals in mCRPC, supporting validation of its tumor-activated TRACTr platform and the broader masking strategy intended to improve the therapeutic window in solid tumors. Its strong balance sheet, with roughly $950M+ in cash at 1Q26, plus multiple pharma partnerships, reduces financing risk and gives it room to advance JANX013 in 2H26 and await the next major JANX007 update in 1H27. The investment case is further strengthened by platform breadth across TRACTr, TRACIr, and ARM programs, alongside a projected JANX007 peak revenue opportunity of about $1.8B in 2035 if tolerability and durability continue to improve.

Janux Therapeutics is viewed negatively because its lead program, JANX007, still faces binary clinical risk, with disappointing efficacy or safety potentially undermining confidence in the tumor-activated platform. The 12/2025 update already disappointed investors, leaving the shares trading at negative EV despite the theoretical opportunity to compete in mCRPC against Pluvicto, which is annualizing about $2B, and despite hopes that taxane-naive data could help. Beyond clinical execution, the company also faces meaningful regulatory, commercial, capital-raising, liquidity, partnership, intellectual property, and supply chain risks that could limit development progress and dilute value.